Posters

      Multiplexed High Content Screening Analysis Reveals Reduced Toxicity Of A Prototypic Modified Risk Tobacco Product (pMRTP) As Compared To A Conventional Cigarette

      Gonzalez-Suarez, I.; Marescotti, D.; Acali, S.; Johne, S. Johne.; Goedertier, D.; Frentzel, S.; Mathis, C.; Hayes, A. W.; Hoeng, J.; Peitsch, M. C.

      Conference date
      Mar 23, 2014
      Conference name

      Society of Toxicology (SOT) 2014
      Link to more information
      Topic
      Summary

      Exposure to Cigarette Smoke (CS) causes lung toxicity and increases the risk of developing Chronic Obstructive Pulmonary Disease and Cancer. Gaining insight into the cellular processes impacted upon exposure would be very useful to understand CS toxicity and aid the development of MRTP products. The aim of the study was to investigate the biological impact of a smoke condensate from a pMRTP product, compared to the reference cigarette 3R4F. For this purpose, we performed a High Content Screening (HCS) analysis on normal human bronchial epithelial cells. 13 multi-parametric indicators of cellular toxicity were measured over range of condensate concentrations and at different time points. Exposure to 3R4F resulted in increased cytotoxicity after 24h. Moreover, compared to vehicle control, 3R4F induced a dose-dependent increase in DNA damage at 4h and 24h. Genotoxicity was accompanied by cell growth arrest, consistent with activation of DNA repair, as well as dose-dependent responses on markers of cellular stress (ROS production, C-Jun activation and glutathione depletion), mitochondrial health (mitochondrial membrane potential and mitochondrial mass) and cellular integrity (cellular membrane permeability). Compared to 3R4F, exposure to a pMRTP product resulted in significant decreases in all tested endpoints at 4h and 24h and more than 90% decrease in cytotoxicity after 24h. In summary, we provide mechanistic insight into the mode of action of CS on lung cells, and how, by lessening the biological impact on key cellular processes, exposure to a pMRTP reduces overall toxicity when compared to CS. Moreover, the ability to detect biological perturbations at sub lethal doses strongly supports the use of HCS-based approaches for toxicological assessment. 

      Related Publications

      Quantitative Adverse Outcome Pathway: A New Prediction Tool to Assess Human Risk of Decreased Lung Function When Switching from Combustible Cigarettes to Heated Tobacco Products

      Systems Toxicology

      An In Vitro Systems Toxicology Assessment of Novel Electronic Vapor Device by Using Air–Liquid Interface Buccal, Bronchial, Small Airway, and Alveolar Culture Models

      Systems Toxicology

      Blood and urine multi-omics analysis of the impact of e-vaping, smoking, and cessation: from exposome to molecular responses

      Systems Toxicology

      Quantitative Modeling of In Vitro Data Using an Adverse Outcome Pathway for the Risk Assessment of Decreased Lung Function in Humans

      Systems Toxicology

      Systems toxicology: The future of risk assessment

      Systems Toxicology

      Systems biology: Methods and applications

      Systems Toxicology

      PMIScience.com is operated by Philip Morris International for the purpose of publishing and disseminating scientific information about Philip Morris International’s efforts in support of its smoke-free product portfolio. This site is a global site for use by scientists, the public health and regulatory communities, and other stakeholders with an interest in tobacco policy. The purpose of this site is not advertising or marketing, nor is it directed at any specific market. It is not intended for use by consumers. New tobacco products sold in the United States are subject to FDA regulation; therefore the content of this site is not intended to make, and nor should it be construed as making, any product related claims in the United States without proper FDA authorization. ​
      ​
      Reduced Risk Products ("RRPs”) is the term we use to refer to products that present, are likely to present, or have the potential to present less risk of harm to smokers who switch to these products versus continuing smoking. PMI has a range of RRPs in various stages of development, scientific assessment and commercialization. All of our RRPs are smoke-free products that deliver nicotine with far lower quantities of harmful and potentially harmful constituents than found in cigarette smoke.